SCHEMBL6491879

SCHEMBL6491879

O=C(Nc1ccc(N2CCN(Cc3ncc[nH]3)CC2)cc1)C1=C(c2ccc(C(F)(F)F)cc2)CCCC1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HIF1A Q16665 7/20 0.46
▸ EPAS1 Q99814 7/20 0.46
▸ MAPKAPK2 P49137 1/20 0.44
▸ KCNH2 Q12809 2/20 0.42
▸ HTR2A P28223 1/20 0.42
▸ HTR7 P34969 1/20 0.42
▸ HTR6 P50406 1/20 0.42
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ CA7 P43166 1/20 0.41
▸ CACNA1G O43497 1/20 0.41
▸ CACNA1B Q00975 1/20 0.41
▸ SLC2A1 P11166 2/20 0.40
▸ DEGS1 O15121 1/20 0.40
▸ LCK P06239 1/20 0.40
▸ HCK P08631 1/20 0.40
▸ SRC P12931 1/20 0.40
▸ KDR P35968 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6492808 0.86 HIF1A (0.46) HIF1AEPAS1MAPKAPK2KCNH2CA1
SCHEMBL6499289 0.85 SRPK1 (0.51) HIF1AEPAS1MAPKAPK2KCNH2CA1
SCHEMBL6499822 0.85 MAPKAPK2 (0.46) HIF1AEPAS1MAPKAPK2KCNH2CA1
SCHEMBL6501870 0.85 SCN9A (0.42) HIF1AEPAS1SLC2A1KDRALDH1A1
SCHEMBL6488640 0.84 SRPK1 (0.51) HIF1AEPAS1MAPKAPK2KCNH2CA1
SCHEMBL6490805 0.84 HIF1A (0.64) HIF1AEPAS1ALDH1A1
SCHEMBL6490755 0.82 CA1 (0.51) HIF1AEPAS1MAPKAPK2KCNH2CA1
SCHEMBL6501481 0.82 CA1 (0.52) HIF1AEPAS1MAPKAPK2KCNH2CA1
SCHEMBL6490778 0.81 MAPKAPK2 (0.46) HIF1AEPAS1MAPKAPK2KCNH2CA1
SCHEMBL6491067 0.80 HIF1A (0.45) HIF1AEPAS1MAPKAPK2KCNH2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 — — US disclosed
EP-1472226-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-03 — — EP disclosed
WO-2003045921-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 HIF1A 2476/4885EPAS1 1386/4885MAPKAPK2 3154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback